Immatics N.V. (NASDAQ:IMTX) Receives $14.67 Average PT from Brokerages

Shares of Immatics N.V. (NASDAQ:IMTX - Get Free Report) have been given an average recommendation of "Buy" by the five analysts that are currently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $14.67.

A number of brokerages recently weighed in on IMTX. Wall Street Zen cut Immatics from a "hold" rating to a "strong sell" rating in a research note on Thursday, May 22nd. Cantor Fitzgerald reissued an "overweight" rating on shares of Immatics in a research report on Tuesday, April 1st. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Immatics in a research report on Wednesday, May 28th. They issued a "buy" rating and a $10.00 price target for the company.

Immatics Trading Up 0.4%

Immatics stock traded up $0.02 during mid-day trading on Friday, hitting $5.46. The company's stock had a trading volume of 679,715 shares, compared to its average volume of 671,328. Immatics has a twelve month low of $3.30 and a twelve month high of $13.09. The stock's fifty day moving average price is $5.15 and its two-hundred day moving average price is $5.33.

Immatics (NASDAQ:IMTX - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.04. Immatics had a negative return on equity of 4.52% and a negative net margin of 14.73%. The business had revenue of $20.12 million for the quarter, compared to analysts' expectations of $14.92 million. On average, research analysts predict that Immatics will post -0.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Y Intercept Hong Kong Ltd acquired a new stake in shares of Immatics during the 4th quarter valued at $211,000. Platinum Investment Management Ltd. boosted its position in Immatics by 53.1% during the fourth quarter. Platinum Investment Management Ltd. now owns 311,722 shares of the company's stock valued at $2,216,000 after purchasing an additional 108,108 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Immatics by 24.6% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company's stock valued at $163,000 after purchasing an additional 4,477 shares in the last quarter. Schroder Investment Management Group increased its position in Immatics by 52.6% in the 4th quarter. Schroder Investment Management Group now owns 427,994 shares of the company's stock worth $2,953,000 after purchasing an additional 147,547 shares during the last quarter. Finally, Wellington Management Group LLP raised its stake in shares of Immatics by 7.6% during the 4th quarter. Wellington Management Group LLP now owns 10,417,892 shares of the company's stock worth $74,071,000 after purchasing an additional 736,709 shares in the last quarter. Institutional investors and hedge funds own 64.41% of the company's stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.